AI Earnings Predictions for Bioventus Inc. (BVS)

EX-99.1

2 bioventusex-991q22026.htm

EX-99.1

Document

Exhibit 99.1

Bioventus Reports Second Quarter Financial Results

•Q2 reported revenue of $153.2 million increased 4%

•Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share

•Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period

•Cash from operations totaled $19.9 million

•Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026

•Company initiates review of strategic alternatives

DURHAM, NC – August 5, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

"Bioventus continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the second half of the year,” said Rob Claypoole, Bioventus President and Chief Executive Officer." We remain focused on disciplined execution while continuing to invest in our four growth drivers. We believe this compelling combination will accelerate revenue growth, strengthen profitability and earnings power, and drive significant free cash flow."

“The Bioventus Board of Directors has full confidence in the business and management team and is excited about the future prospects of the Company,” Claypoole continued. “At the same time, in light of the external interest we have received, the Board has formed a committee of independent directors, which has determined it is the right time to initiate a review of strategic alternatives. This decision reflects our steadfast commitment to exploring all opportunities to maximize value for our shareholders.”

Second Quarter 2026 Financial Results

For the second quarter, worldwide revenue of $153.2 million advanced 4%, driven by double-digit growth in Pain Treatments.

Net income attributed to Bioventus Inc. was $33.4 million, compared to $7.5 million in the prior-year period. In addition to higher operating profit driven by an increase in revenue, net income attributable to Bioventus Inc. benefited from the removal of the $24.6 million valuation allowance associated with the Company's deferred tax asset.

Adjusted EBITDA* of $35.3 million advanced 4% from $33.8 million in the prior-year period due to higher revenue growth, which was partially offset by increased investment to fund future growth.

GAAP earnings of $0.47 per diluted share of Class A common stock improved from $0.11 per diluted share in the prior-year period. Non-GAAP earnings of Class A common stock* of $0.22 per diluted share reflects an increase of 5% from $0.21 per diluted share in the prior-year period, driven by improved operating profit and lower interest expense.

*See below under “Use of Non-GAAP Financial Measures” for more details.

Revenue By Business

The following tables represent net sales by business and geographic region for the three months ended June 27, 2026 and June 28, 2025:

Three Months Ended

Change as Reported

Constant

Currency*

Change

(in thousands, except for percentage)

June 27, 2026

June 28, 2025

$

%

%

Pain treatments

$

81,748

$

73,308

$

8,440

11.5

%

11.3

%

Surgical solutions

50,352

52,716

(2,364)

(4.5

%)

(4.6

%)

Restorative therapies

21,108

21,636

(528)

(2.4

%)

(2.5

%)

Total net sales

$

153,208

$

147,660

$

5,548

3.8

%

3.6

%

Pain Treatments: Global revenue of $81.7 million increased 11.5%, reflecting strong volume growth in the Company's Durolane hyaluronic acid therapy along with favorable customer mix relative to the second quarter of 2025.

Surgical Solutions: Global revenue of $50.4 million decreased 4.5%, due to a challenging prior-year comparison, and a shift in timing of certain Ultrasonics capital placements and international orders to the second half of the year.

Restorative Therapies: Global revenue of $21.1 million decreased 2.4% due to a change in customer mix, specifically with Medicare patients, for the EXOGEN Bone Stimulation System in addition to a challenging comparison to the prior year.

Three Months Ended

Change as Reported

Constant Currency* Change

(in thousands, except for percentage)

June 27, 2026

June 28, 2025

$

%

%

U.S.

Pain Treatments

$

72,704

$

64,436

$

8,268

12.8

%

12.8

%

Surgical Solutions

43,585

45,747

(2,162)

(4.7

%)

(4.7

%)

Restorative Therapies

18,176

18,592

(416)

(2.2

%)

(2.2

%)

Total U.S. net sales

134,465

128,775

5,690

4.4

%

4.4

%

International

Pain Treatments

9,044

8,872

172

1.9

%

0.5

%

Surgical Solutions

6,767

6,969

(202)

(2.9

%)

(3.7

%)

Restorative Therapies

2,932

3,044

(112)

(3.7

%)

(4.2

%)

Total International net sales

18,743

18,885

(142)

(0.8

%)

(1.8

%)

Total net sales

$

153,208

$

147,660

$

5,548

3.8

%

3.6

%

U.S.: Revenue of $134.5 million incr

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784382632.d64958a7

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

bvs-202603050001665988FALSE00016659882026-03-052026-03-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026

Bioventus Inc. (Exact name of registrant as specified in charter)

Delaware

001-37844

81-0980861

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (919) 474-6700 N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17     CFR 240.14d-2(b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common Stock, $0.001 par value per share

BVS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒

Item 2.02. Results of Operations and Financial Condition. On March 5, 2026, Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits. (d)Exhibits.

Exhibit No.

Description

99.1

Press Release Dated March 5, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOVENTUS INC.

Date: March 5, 2026 By: /s/ Anthony D’Adamio

Anthony D’Adamio Senior Vice President and General Counsel